Wockhardt Limited reported a strong financial performance for the quarter and year ended March 31, 2026. The company achieved a 30% revenue growth in Q4 FY26, reaching Rs. 965 crore, and a positive Profit Before Tax (PBT) of Rs. 238 crore for the full financial year. This growth was driven by a robust performance in its Biotech segment, expanding international market presence, and significant progress in its novel antibiotic pipeline.
Financial Performance Overview
For the fourth quarter of the financial year 2025-26, Wockhardt reported a total revenue of Rs. 965 crore, marking a 30% increase compared to the same period in the previous year. The company’s EBITDA for the quarter stood at Rs. 196 crore, representing a 147% growth. On an annual basis, total revenue reached Rs. 3,373 crore, an 11% growth over FY25, while the annual EBITDA grew by 51% to Rs. 630 crore.
Segment Growth and Biotech Expansion
The company’s Biotech operations served as a significant growth engine, recording a 126% growth in Q4 FY26 compared to Q4 FY25, with revenues reaching Rs. 252 crore for the quarter. Full-year Biotech revenue stood at Rs. 697 crore, a 27% increase year-on-year. This success is attributed to strong demand in emerging markets and strategic acquisitions in key regions including Thailand, Egypt, Algeria, and LATAM.
Regional Highlights
Wockhardt saw consistent performance across its core markets. The India Branded Business grew by 18% in Q4 FY26, driven by diabetic therapy and the introduction of its regenerative derma segment. The UK region also delivered a strong performance with 20% growth in the final quarter. Meanwhile, the Emerging Markets segment posted an impressive 124% quarterly growth, largely fueled by the company’s Biotech Insulin offerings.
Novel Antibiotic Pipeline Progress
Wockhardt continues to advance its R&D portfolio, with five novel antibiotics successfully completing Phase 3 Clinical Trials: Emrok®, Emrok O®, Miqnaf®, Zaynich®, and Foviscu®. Notably, Zaynich® has received accelerated assessment status from the EMA, highlighting its potential to treat resistant Gram-negative infections. Additionally, the company filed 1 new patent during the quarter, bringing its cumulative total to 3,290 filings and holding 859 patents globally.
Source: BSE
